Zepeda VTC, Hernández SJR, Tenopala VS, Martínez AR, Nuñez QG, Ocampo AL, Torres HJC, Velázquez RV

Language: Spanish
References: 15
Page:
PDF size: 45.34 Kb.

ABSTRACT

Objetive: To evaluate the analgesic quality of the C. Tramadol by oral administration compared with the administration of itself along with amitriptiline and gabapentine in the diabetic neuropathy. Material and Methods: A study was performed for 4 weeks in patients of both sexes from 40 to 70 years and algologic diagnose of diabetic neuropathy controlled with glucemia, and these were divided into 3 groups. These groups received Tramadol by oral administration 200 mg/day at the begining, this was incremented in the following weeks according to the EVA registered, up to a maximum of mg/day. Preestablished doses of Amitriptiline 25 mg and Gabapentine mg were added per day to the groups II and III respectively. The EVA and the side-effects were registered. Results: The diabetic neuropathy prevails in the femenine sex (p‹0.05), the EVA value diminished in the 3 groups, with prevalence in groups II and III in the 2th. week, not being significant at the end of the study. The requirement of Tramadol was smaller in the group II compared with the other two groups which represented a significant statiscally difference p‹0.05. The undersirable effects as sedation, nausea, constipations prevailed in groups I and III (p‹0.05), while dry mouth in group II. Discusion: Tramadol is a drug that contributes to analgesia in the diabetic neuropathy, but it requires to be associated with neuromodulators, for a good pain control.

REFERENCES

1. Frati A. Araiza. R. Neuropatía Diabética. México : Temas de Medicina Interna 1993; 4 (1): 803.

2. Frati A. Araiza. R Tratamiento Neuropatía Diabética. Gace. Med. Méx. 1998; Volumen 134 (1): 85-92.

3. Rodríguez – Carranza S. Vega Boada F, Garc ía Ramos G. Neuropatía Diabética. México. : Temas de Medicina Interna 1996: 4 (4): 765.

4. Martyn C. Hughes R. Epidemiology of Peripheral Neuropathy J. Neurosurg and Psycheiart 1997; (62):310.

5. Wright Jm Review of The Symptomatic Treatment of Diabetic Neuropathy, Pharmacotherapy 1994;14:689-97.

6. Mc Quay H, Carroll D, Jadad Ar Wiffen P Anticonvulsant Drugs for Management of Pain: A Systematic Review BMJ 1995;311:1047-5.2

7. Magni C .The Use of Antidepressants In The Tretment of Chronic Pain. Drugs 1991;42:730-748.

8. Collat L . Luthy C. Dayer. Multimodal Analgesic Effect of Tramadol. Clin. Pharmacol Ther 1993:53:223.

9. Rad Bruch–L. Et .Al, A Risk–Benefit . Assessments of Tramadol in the Manegement of Pain. Drugs Saf. 1996 Jul. ;15(1):8-29.

10. Raffa Rb Friedrich F. Opioid And Non Opioid Components Independently Contribute to the Mecahanisms of Action of Tramadol, an Atypical Opioid Analgesic J. Pharmacol Experimental Theral. 1982 ;8:28-42.

11. M. Serrano; A. Cañas. Beneficio de la combinación Keterolaco Tramadol en el tratamiento del Dolor Postoperatorio Red. Soc. Esp. Dolor 4:317-324, 1997.

12. Tamez Pérez H. M. Rodríguez A. Uso de Gabapentina y en la neuropatía Diabética Dolorosa. Med. Int. Méx. 1998 Volumen 14 (6): 251-253.

13. Wetzel Ch, Connelly J.F. Use Of Gabapentin in Pain Management. Ann Pharmacother 1997 1;9:1082-3.

14. S, Hughes J. Singh L. Gabapentin, Isobutylgaba Represent a Novel Class of Antihyperalgesic Agent Br. J. Pharmacol 1997;121(8):1513-22.

15. Mitchell B Max. Md .Effects Of Desipramine, Amitriptilin and Fluoxetine on Pain in Deabetic Neuropathy the New England, Jounal of Medecine May 7 1992 ;1250-56.